See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
The Oscars
Volodymyr Zelenskyy
Ukraine War
Academy Awards
Social Media
Artificial Intelligence
Baseball
Donald Trump
Basketball
Tariffs
Athletics
European Union
Published • loading... • Updated

Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma

  • Innovent Biologics has dosed the first patient in a pivotal study of IBI363, a PD-1/IL-2 bispecific antibody, compared to pembrolizumab for melanoma treatment.
  • The primary goal of the study is to improve progression-free survival rates in patients with advanced melanoma who have not received prior systemic therapy.
  • Phase 1 and 2 studies showed IBI363 had an overall objective response rate of 61.5% and a disease control rate of 84.6%, higher than current therapies in China.
  • The trial aims to validate IBI363's effectiveness in converting 'cold tumors' to 'hot tumors' by activating both PD-1 and IL-2 pathways, according to Hui Zhou, Senior Vice President of Innovent.
Insights by Ground AI
Does this summary seem wrong?

15 Articles

All
Left
Center
6
Right
NatureNature

The diverse functions of the PD1 inhibitory pathway

In this Review, the authors detail the complex expression patterns and regulation of programmed cell death protein 1 (PD1) and its ligands. The authors focus on the importance of understanding these pathways in order to optimize the efficiency and safety of immune checkpoint blockade in patients. T cell activation is a highly regulated process involving peptide–MHC engagement of the T cell receptor and positive costimulatory signals. Upon activa…

·United Kingdom
Read Full Article
Longview Daily NewsLongview Daily News
+11 Reposted by 11 other sources

Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma

SAN FRANCISCO and SUZHOU, China, March 2, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major…

Read Full Article
pipelinereviewpipelinereview

Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma - Pipelinereview

SAN FRANCISCO, CA, USA and SUZHOU, China I March 2, 2025 I Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the first patient has been dosed in its registrational study evaluating IBI363, a first-in-class …

Read Full Article
ScienceDirectScienceDirect

PD-1-mediated inhibition of T cell activation: Mechanisms and strategies for cancer combination immunotherapy

The programmed cell death 1 (PD-1) immune checkpoint of co-inhibitory signaling plays crucial roles in controlling the magnitude and duration of T cel…

·Amsterdam, Netherlands
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Missoulian broke the news in Missoula, United States on Monday, March 3, 2025.
Sources are mostly out of (0)

Similar News Topics

China

China

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
Search
BlindspotLocal